WO2004087150A1 - Composition pour medicaments - Google Patents

Composition pour medicaments Download PDF

Info

Publication number
WO2004087150A1
WO2004087150A1 PCT/JP2004/004633 JP2004004633W WO2004087150A1 WO 2004087150 A1 WO2004087150 A1 WO 2004087150A1 JP 2004004633 W JP2004004633 W JP 2004004633W WO 2004087150 A1 WO2004087150 A1 WO 2004087150A1
Authority
WO
WIPO (PCT)
Prior art keywords
lung disease
asthma
treating
leukotriene antagonist
preventing
Prior art date
Application number
PCT/JP2004/004633
Other languages
English (en)
Japanese (ja)
Inventor
Motoya Mie
Yuko Takashima
Haruhiko Manabe
Original Assignee
Kyowa Hakko Kogyo Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co. Ltd. filed Critical Kyowa Hakko Kogyo Co. Ltd.
Priority to JP2005504271A priority Critical patent/JPWO2004087150A1/ja
Publication of WO2004087150A1 publication Critical patent/WO2004087150A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the present invention relates to a pharmaceutical composition containing a phosphodiesterase IV inhibitor (PDE-IV inhibitor) and a leukotriene antagonist.
  • PDE-IV inhibitor phosphodiesterase IV inhibitor
  • leukotriene antagonist a phosphodiesterase IV inhibitor
  • An object of the present invention is to provide 7- [2- (3,5-dichloro-4-pyridyl) -11-oxoethyl] —4-methoxyspiro [1,3-benzodioxo-l-2,1,1-cyclopentane]
  • Another object of the present invention is to provide a pharmaceutical composition containing a pharmacologically acceptable salt thereof and a leukotriene antagonist.
  • the present invention relates to the following (1) to (26).
  • lung disease is a disease selected from asthma, bronchial asthma and COPD.
  • the leukotriene antagonist is a compound selected from the group consisting of pranlukast, zafirlukast and montelukast sodium.
  • kits for treating and / or preventing lung disease comprising a first component containing a pharmacologically acceptable salt and (b) a second component containing a leukotriene antagonist.
  • the leukotriene antagonist is a compound selected from the group consisting of pranlukast, zafirlukast and sodium montelukast.
  • Equation (I) In represented 7- [2 - (3, 5-dichloro one 4-pyridyl) Single 1- Okisoechiru] - 4-methoxy-one Spiro [1, 3 Benzojiokiso one route 2, 1 5 - cyclopentane] or a drug
  • a physiologically acceptable salt comprising administering a physiologically acceptable salt and (b) a leukotriene antagonist simultaneously or separately at an interval.
  • Lung disease is selected from asthma, bronchial asthma and COPD
  • lung disease is a disease selected from asthma, bronchial asthma and COPD.
  • Pharmaceutically acceptable salts of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
  • Pharmaceutically acceptable acid addition salts of compound (I) include inorganic acid salts such as hydrochloride, sulfate, hydrobromide, nitrate and phosphate, acetate, mesylate, and succinate Organic salts such as maleate, maleate, fumarate, citrate, and tartrate; and pharmacologically acceptable metal salts include alkali metal salts such as sodium salt and potassium salt. , Magnesium salts, calcium salts and other alkaline earth metal salts, aluminum salts, zinc salts, etc., and pharmacologically acceptable ammonium salts include ammonium salts, tetramethyl ammonium salts, etc.
  • organic amine addition salts such as morpholine and piperidine.
  • Pharmacologically acceptable amino acid addition salts include glycine and glycine. Et two Ruaranin, lysine, Asuparagin acid addition salts such as glutamic acid.
  • Compound (I) can be produced by the method described in W096 / 36624.
  • Compound (I) may exist in stereoisomers such as tautomers, and the pharmaceutical composition of the present invention, a therapeutic and / or prophylactic agent for pulmonary disease, a kit, and a therapeutic and / or therapeutic agent for pulmonary disease
  • a prophylactic kit and a method for treating and / or preventing lung disease all possible isomers and mixtures thereof, including these, can be used.
  • Compound (I) of the present invention includes these compounds. Including all possible isomers and mixtures thereof.
  • Compound (I) and its pharmacologically acceptable salts may exist in the form of adducts with water or various solvents, and these adducts are also present in the pharmaceutical composition of the present invention, And a kit for treating and / or preventing lung disease and a method for treating and / or preventing lung disease; and the compound (I) of the present invention or its pharmacology. Is included in the salts that are acceptable.
  • the leukotriene antagonist may be any as long as it has an antagonistic action on leukotriene receptor,
  • Examples include montelukast (mon t e 1 uka st) represented by the formula (C), and these may be used alone or in combination.
  • leukotriene antagonists include pharmacologically acceptable salts (the pharmacologically acceptable salts include, for example, the salts exemplified as the pharmacologically acceptable salts of the compound (I) above). Or a hydrate thereof, but may be a pharmaceutical composition of the present invention, a therapeutic and / or prophylactic agent for lung disease, or a kit, a kit for treating and / or preventing lung disease, and a kit for treating lung disease. These can also be used for treatment and / or prophylaxis. Further, among these leukotriene antagonists, one or more asymmetric carbons and the like are present, and some have two or more stereoisomers. Products, lung cancer treatment and Z or prophylactic agents, kits, lung disease treatment and 7 or prevention kits and lung disease treatment and Z or prevention methods include all possible isomers and their Mixtures can be used.
  • Leukotriene antagonists preferably used include, for example, pranlukast, zafirlukast, montelukast sodium and the like.
  • the pharmaceutical composition and kit of the present invention can be used, for example, for the treatment of pulmonary diseases, and more specifically, asthma, bronchial asthma, COPD, emphysema, chronic bronchitis, adult respiratory distress syndrome, interstitial It can be used to treat pneumonia, pulmonary fibrosis, eosinophilic pneumonia, etc.
  • the compound (I) or the pharmaceutically acceptable salt thereof and the leukotriene antagonist used in the pharmaceutical composition of the present invention or the therapeutic and / or prophylactic agent for pulmonary disease include these active ingredients. As long as it is formulated so as to contain it, it can be used or administered as a single agent (mixture) or in combination with a plurality of preparations. Among them, a combination of two or more preparations is preferable. When used or administered as a combination of multiple preparations, they can be used or administered simultaneously or separately at intervals. These preparations are preferably used in the form of, for example, tablets, injections, or inhalants such as dry powder and aerosol.
  • the dose ratio (weight / weight) of the compound (I) or a pharmacologically acceptable salt thereof to the leukotriene antagonist is appropriately adjusted according to the combination of the leukotriene antagonist used, the efficacy of the leukotriene antagonist, and the like. Specifically, for example, 1Z50 (compound (I) or a pharmaceutically acceptable salt thereof Z-leukotriene antagonist) ⁇
  • the ratio is between 5000/1, more preferably between 1/10 and 1000/1.
  • a compound containing (a) a compound (I) or a first component containing a pharmacologically acceptable salt thereof, and (b) a compound containing a leukotriene antagonist
  • a compound containing (a) a compound (I) or a first component containing a pharmacologically acceptable salt thereof, and (b) a compound containing a leukotriene antagonist
  • Each of the two components is separately formulated as described above, and prepared as a kit. Using the kit, the components are simultaneously or at different times, and the same route or different routes to the same subject. Can also be administered.
  • the kit includes, for example, components that are contents caused by external temperature or light during storage. Material and shape are not particularly limited as long as denaturation and elution of chemical components from the container are not observed.
  • the container consists of two or more containers (for example, vials and bags) and the contents.
  • a component in which the first component and the second component have a form that can be administered via separate routes (eg, a tube or the like) or the same route is used.
  • Specific examples include kits for tablets, injections, inhalants, and the like. Inhalation kits can be combined with commonly used metered dose inhalers (MDIs), powder inhalers, etc. to provide one or more for the administration of the first and second components. May be included.
  • MDIs metered dose inhalers
  • the capsule is compatible with the delivery of the dry powder from the capsule.
  • a dry powder inhaler or the like may be included.
  • the kit also includes a multi-dose dry powder inhaler (MDP I) in which the drug storage part comprises the drug storage part containing the first component dry powder and the drug storage part containing the second component dry powder. .
  • MDP I multi-dose dry powder inhaler
  • the method for treating and / or preventing lung disease of the present invention comprises the use of the above-mentioned pharmaceutical composition or the compound (I) or a pharmacologically acceptable compound thereof for use in an agent for treating and / or preventing lung disease.
  • the method of using or administering the salt and leukotriene antagonist to be used comprises, the compound (I) or a pharmacologically acceptable salt thereof and a leukotriene antagonist are formulated so as to contain the active ingredients thereof, for example, as a single agent or as a combination of a plurality of formulations, preferably It can be carried out by administering two or more formulations in combination.
  • these preparations can be administered simultaneously or separately at intervals, and can also be administered using a kit as described above.
  • Guinea pigs (350-500 g) are exsanguinated and killed under ether anesthesia, and the bronchi are removed and zigzag specimens are prepared. Craves Henzelite as a nutrient solution
  • Test Example 2 Inhibitory effect of combined administration of compound (I) and leukotriene receptor antagonist on airway absorption induced by antigen-antibody reaction
  • the test is performed in a well-known manner.
  • guinea pigs Male Hartiey guinea pigs (Japan SLC) were used.
  • the guinea pigs were housed in aluminum cages at a room temperature of 19 to 25 ° C, humidity of 30 to 70%, and illuminated for 12 hours a day (7:00 am to 3:00 pm). And were fed with water ad libitum.
  • (I) lactose preparation was added to a 0.125% w / v tyloxapol aqueous solution (AREVEL: registered trademark, manufactured by Azur Corporation) so that the concentration of compound (I) was 10 mg / mL.
  • a suspension for administration of compound (I) was prepared.
  • a suspension for administration of pranlukast was prepared by suspending a 0.5% w / v% methylcellulose 400 (manufactured by Wako Pure Chemical Industries, Ltd.) aqueous solution such that the concentration of pranlukast was 0.3 mg / ml.
  • lactose dissolved in a 0.125% by weight / volume aqueous tyloxapol solution at a concentration of 5 Omg / mL was used as a solvent for administration.
  • a suspension for administration of pranlukast or an aqueous solution of 0.5% by weight Z volume% methylcellulose 400 was orally administered at a dose of 1 OmLZkg. Then, to each group, a suspension for administration of Compound (I) or a vehicle for administration was administered into the respiratory tract at a dose of 1 mL / kg 30 minutes before inhalation of the antigen.
  • a 0.5% w / v% aqueous solution of methylcellulose 400 was orally administered, and a group to which the administration solvent was administered into the respiratory tract 30 minutes before was designated as a solvent administration group.
  • the airway resistance after the antigen administration was measured by Biosystem XA (Vaxco).
  • the area under the curve (AUC) was calculated with respect to the ratio (%) of the change in airway resistance 15 minutes after inhalation of the antigen to the average value of airway resistance before inhalation of the antigen, and used as an index of airway contraction.
  • the airway contraction inhibition rate by each of these alone or in combination was calculated as follows.
  • cysteinyl leukotriene was included in the airway constriction response in the above test.
  • Cys LT s has been reported to be involved [Eur. J. Pharmacol., Vol. 235, pp. 211-219 (1993); Eur. J. Pharmacol., 403, 169-179 Page (2000)]. CysLTs are not limited to airway constriction in patients with asthma [J. Allergy Cl in. Immuno 1., Vol. 102, pp. 177-183 (1998)] Has also been reported to be involved in airway constriction in patients with COPD [Palmonary Pharmacol. 'And' Therapeutics (Pulm. Pharmaco.
  • the pharmaceutical composition or the therapeutic and / or prophylactic agent for pulmonary disease usable in the present invention comprises compound (I) or a pharmacologically acceptable salt thereof, a leukotriene antagonist and an active ingredient thereof.
  • compound (I) or a pharmacologically acceptable salt thereof, a leukotriene antagonist and an active ingredient thereof As long as it is formulated to contain it, it can be used, administered or manufactured as a single agent or as a combination of multiple agents.
  • These pharmaceutical compositions or agents for treating and / or preventing lung diseases are preferably in unit dosage forms suitable for oral administration such as tablets or parenteral administration such as inhalants and injections. Good. When used or administered as a combination of a plurality of preparations, they can be used or administered simultaneously or separately at an interval.
  • preparations contain, in addition to the active ingredient, pharmaceutically acceptable diluents, excipients, It can be prepared by an ordinary method using a disintegrant, a lubricant, a binder, a surfactant, water, physiological saline, a vegetable oil solubilizer, an isotonic agent, a preservative, an antioxidant, and the like as appropriate. it can.
  • excipients such as lactose, disintegrants such as starch, lubricants such as magnesium stearate, binders such as hydroxypropylcellulose, surfactants such as fatty acid esters, glycerin and the like
  • a plasticizer or the like may be used according to a conventional method.
  • water physiological saline
  • vegetable oil such as soybean oil
  • various solvents solubilizing agents, isotonic agents, preservatives, antioxidants and the like may be used in a conventional manner.
  • Inhalants are also prepared by making the active ingredient into a powder or a liquid, compounding it in an inhalation propellant or carrier, and filling into an appropriate inhalation container.
  • a conventional mechanical powder inhaler can be used
  • an inhaler such as a nebulizer
  • conventionally known inhalation propellants can be widely used, and CFC-11, CFC-12, CFC-21, CFC-22, CFC113, CFC114, CFC123, CFC-142c, 1 CFC 134a, 1 CFC
  • chlorofluorocarbons such as C318, 1,1,1,2-tetrafluoroethane, hydrocarbons such as propane, isoprene, n-butane, and ethers such as Jethyl ether
  • compressed gas such as nitrogen gas and carbon dioxide gas.
  • preservatives flavors, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, and the like exemplified above. It is also possible to add more auxiliary components.
  • the dose and frequency of administration of the compound and its pharmacologically acceptable salt are determined by the dosage form, although it depends on the patient's age, weight, symptoms, etc., it is usually preferable to administer Compound (I) or a pharmaceutically acceptable salt thereof and a leukotriene antagonist at a lower dose per day.
  • compound (I) or a pharmaceutically acceptable salt thereof and a leukotriene antagonist may be administered to an adult at a rate of 0.01 to l OOOmg and 0.01 to 200 mg per adult, respectively.
  • Compound (I) or a pharmaceutically acceptable salt thereof and a leukotriene antagonist may be administered to an adult at a dose of 1 ⁇ to 500111 ⁇ and 1 ⁇ , respectively.
  • the dose and the number of administrations of the compound and the pharmacologically acceptable salt are determined by the dosage form, although it depends on the patient's age, weight, symptoms, etc., it is preferable to prepare, use or administer as a single preparation at each dose when used or administered as a combination of a plurality of the above preparations.
  • a tablet having the following composition is prepared.
  • Compound (I) 40 g, lactose
  • a tablet having the following composition is prepared by a conventional method. Montelukast sodium 20 g, 294.8 g of lactose and 72 g of potato starch are mixed, and 120 g of a 10% aqueous solution of hydroxypropyl cellulose is added thereto. This mixture is kneaded by a conventional method, granulated, dried, and then sized to obtain granules for tableting. To this, 1.2 g of magnesium stearate was added and mixed, and the mixture was tableted with a tableting machine (RT-15 type, manufactured by Kikusui) having a punch of 8 mm in diameter, and tablets (1 active ingredient per tablet) were pressed. Omg).
  • RT-15 type manufactured by Kikusui
  • An injection having the following composition is prepared by a conventional method.
  • Compound (I) lg is dissolved in purified soybean oil, and 12 g of purified egg yolk lecithin and 25 g of glycerin for injection are added. This The mixture is kneaded and emulsified to 100 OmL with distilled water for injection in a conventional manner. The resulting dispersion is aseptically filtered using a 0.2 ⁇ m disposable pull-type membrane filter, and then aseptically filled into glass vials in 2 mL increments for injection (containing 2 nig of active ingredient per vial). ).
  • Example 5 Injection (Pranlukast hydrate)
  • An injection having the following composition is prepared by a conventional method. Dissolve 15 g of pranlukast hydrate in purified soybean oil and add 12 g of purified egg yolk lecithin and 25 g of glycerin for injection. This mixture is kneaded and emulsified to 100 OmL with distilled water for injection by a conventional method. The resulting dispersion was aseptically filtered through a 0.2-m disposable membrane filter, and aseptically filled into glass vials in 2 mL increments for injection (30 mg of active ingredient per vial). Is obtained.
  • An injection having the following composition is prepared by a conventional method.
  • Compound (I) lg and pranlukast hydrate (15 g) are dissolved in purified soybean oil, and purified egg yolk lecithin (12 g) and glycerin for injection (25 g) are added.
  • This mixture is kneaded and emulsified with distilled water for injection to make up to 100 OmL by a conventional method.
  • the resulting dispersion was aseptically filtered using a 0.2 / m disposable membrane filter, and aseptically filled into glass vials in 2 mL increments. Injection (containing 2 mg of compound (I) and 30 mg of fuplanukast hydrate per vial) is obtained.
  • a dry powder inhalant having the following composition by the usual method.
  • the compound (I) is pulverized using a jet mill (volume average particle size: 5 to 2 ⁇ m).
  • the resulting powdered compound (I) and lactose are mixed at a weight ratio of 1: 5 to obtain a dry powder preparation.
  • the preparation can be administered with a dry powder inhaler for ⁇ .
  • Example 8 Dry powder inhalant (zafirlukast)
  • a dry powder inhaler having the following composition is prepared by a conventional method. Pulverize zafirlukast using a jet mill (volume average particle size: 5 to 2 Ojm). The resulting milled zafirlukast and lactose (Pharmatose 325M; registered trademark, manufactured by DMV) are mixed at a weight ratio of 1:10 to obtain a dry powder preparation. The formulation can be administered with a conventional dry powder inhaler.
  • Example 9 Dry powder inhalant (single agent of compound (I) and zafirlukast) A dry powder inhalant having the following composition is prepared by a conventional method. Jet mill The compound (I) and zafirlukast are each crushed (volume average particle size: 5-20 zm). The weight ratio of the obtained compound (I), each crushed product of zafirlukast and lactose (Pharmatose 325 M; registered trademark, manufactured by DMV)
  • the formulation can be administered with a conventional dry powder inhaler.
  • the present invention 7 - [2- (3 5-dichloro port one 4-pyridyl) Single 1- Okisoechi Le I-4-menu Tokishisupiro [1 3 pens zone di O benzodioxole-2, 1 5 - Shikuropen Tan] or There is provided a pharmaceutical composition containing the pharmacologically acceptable salt thereof and a leukotriene antagonist.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant 7-[2-(3,5-dichloro-4-pyridyle)-1-oxoéthyl]-4-méthoxy-spiro[1,3-benzodioxole-2,1'-cyclopentane] ou un de ses sels pharmaceutiquement acceptable et un antagoniste du leukotriène. L'invention concerne, en particulier, un médicament et/ou un agent de prévention contre des maladies pulmonaires comprenant 7-[2-(3,5-dichloro-4-pyridyle)-1-oxoéthyl]-4-méthoxy-spiro[1,3-benzodioxole-2,1'-cyclopentane] ou un de ses sels pharmaceutiquement acceptable et un antagoniste du leukotriène, lesdits ingrédients étant administrés simultanément ou séparément à intervalles.
PCT/JP2004/004633 2003-03-31 2004-03-31 Composition pour medicaments WO2004087150A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005504271A JPWO2004087150A1 (ja) 2003-03-31 2004-03-31 医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003094510 2003-03-31
JP2003-094510 2003-03-31

Publications (1)

Publication Number Publication Date
WO2004087150A1 true WO2004087150A1 (fr) 2004-10-14

Family

ID=33127396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004633 WO2004087150A1 (fr) 2003-03-31 2004-03-31 Composition pour medicaments

Country Status (2)

Country Link
JP (1) JPWO2004087150A1 (fr)
WO (1) WO2004087150A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036624A1 (fr) * 1995-05-19 1996-11-21 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques contenant de l'oxygene
WO2001057036A1 (fr) * 2000-01-31 2001-08-09 Pfizer Products Inc. Derives benzocondenses heterocycliques de nicotinamide utiles comme inhibiteurs selectifs d'isozymes pde4
WO2001064639A2 (fr) * 2000-03-02 2001-09-07 Merck Frosst Canada & Co. Amides inhibant la pde iv, compositions et procedes de traitement
WO2002038155A1 (fr) * 2000-11-07 2002-05-16 Merck & Co., Inc. Procede de traitement au moyen d'une combinaison d'un inhibiteur de pde4 et d'un antagoniste de leucotriene
WO2003066044A1 (fr) * 2002-02-08 2003-08-14 Kyowa Hakko Kogyo Co., Ltd. Nouvelles compositions de medicaments contenant, outre des anticholinergiques, des composes heterocycliques
WO2004005276A1 (fr) * 2002-07-03 2004-01-15 Kyowa Hakko Kogyo Co., Ltd. Methode de preparation de derives de 1,3-benzodioxole-2-spiro-cycloalcane

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036624A1 (fr) * 1995-05-19 1996-11-21 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques contenant de l'oxygene
WO2001057036A1 (fr) * 2000-01-31 2001-08-09 Pfizer Products Inc. Derives benzocondenses heterocycliques de nicotinamide utiles comme inhibiteurs selectifs d'isozymes pde4
WO2001064639A2 (fr) * 2000-03-02 2001-09-07 Merck Frosst Canada & Co. Amides inhibant la pde iv, compositions et procedes de traitement
WO2002038155A1 (fr) * 2000-11-07 2002-05-16 Merck & Co., Inc. Procede de traitement au moyen d'une combinaison d'un inhibiteur de pde4 et d'un antagoniste de leucotriene
WO2003066044A1 (fr) * 2002-02-08 2003-08-14 Kyowa Hakko Kogyo Co., Ltd. Nouvelles compositions de medicaments contenant, outre des anticholinergiques, des composes heterocycliques
WO2004005276A1 (fr) * 2002-07-03 2004-01-15 Kyowa Hakko Kogyo Co., Ltd. Methode de preparation de derives de 1,3-benzodioxole-2-spiro-cycloalcane

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHIYAMA YUJI ET AL: "PHARMACIA", JIKAN CHIRYO E MUKETE, vol. 34, no. 6, 1998, pages 573 - 578, XP002981593 *

Also Published As

Publication number Publication date
JPWO2004087150A1 (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
US20050232871A1 (en) Use of compounds in a dry powder inhaler
RU2010108640A (ru) Новая комбинация терапевтических агентов
US20100272811A1 (en) Complex of trospium and pharmaceutical compositions thereof
CA3133189A1 (fr) Methodes de traitement de l'influenza chez les sujets atteints de l'influenza et presentant un facteur de risque de complication
WO2004096274A1 (fr) Medicament administre par voie orale
WO2004087150A1 (fr) Composition pour medicaments
WO2010097114A1 (fr) Nouvelle combinaison d'agents thérapeutiques
WO2020194042A1 (fr) Traitement de la grippe au moyen de dérivés de pyridone polycyclique substitués et de promédicaments de ceux-ci chez un sujet ayant une grippe et un état associé à une grippe sévère
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
JP2005206485A (ja) イソキノリンスルホンアミド誘導体を含有する医薬
WO2004087149A1 (fr) Composition therapeutique
WO2004087151A1 (fr) Composition medicinale
WO2023126437A1 (fr) Traitement de troubles cardio-pulmonaires
AU2022424376A1 (en) Treatment of cardiopulmonary disorders
WO2023126438A1 (fr) Formulation pharmaceutique de poudre sèche à inhaler
AU2022427770A1 (en) Pharmaceutical dry powder inhalation formulation
WO2004087148A1 (fr) Agent therapeutique et/ou agent prophylactique destine aux maladies pulmonaires
AU2024203957A1 (en) Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2005102344A1 (fr) Composition pharmaceutique
JP2003104890A (ja) 慢性閉塞性肺疾患治療薬
JP2004300064A (ja) 医薬組成物
WO2005056009A1 (fr) Agent therapeutique pour une maladie pulmonaire
JP2005015394A (ja) 医薬組成物
AU2002330687A1 (en) Inhalation compositions comprising tricyclis 5,6-dihydro-9H-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines
JP2005047834A (ja) 医薬組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005504271

Country of ref document: JP

122 Ep: pct application non-entry in european phase